POS1242 FACTORS ASSOCIATED WITH MORTALITY IN PATIENTS WITH RHEUMATIC DISEASES AND COVID-19 IN MEXICO
Authors: D. Alpizar-Rodriguez, F. Irazoque-Palazuelos, T. S. Rodriguez-Reyne, E. Zamora, D. X. Xibille Friedmann, A. Castillo Ortiz, M. U. Martínez-Martínez, B. E. Zazueta, S. Duran Barragan, M. Rull-Gabayet, M. Vázquez-Del Mercado Espinosa, J. F. Moctezuma-Ríos, A. Barragán-Garfías, E. Martin-Nares, D. Cervantes-Rosete, D. Vega-Morales, M. Aguiar Castellanos, G. Reyes, M. Macias, L. V. Maya-Piña, F. Cobos-Villanueva, J. E. Navarro-Zarza, A. Sanchez-Rodriguez, M. D. P. Cruz-Domínguez, X. Jimenez Jimenez, O. Marquez, A. Martínez, A. Vargas Guerrero, L. Andrade, C. F. Pacheco Tena
Journal: Annals of the Rheumatic Diseases (2021)

Background: As of the 25th of January 2021, more than 150 thousand deaths as consequence of COVID-19 have been reported in Mexico [1]. Advanced age, male gender and comorbidities have been described as risk factors for severe disease and mortality in general population [2]. COVID-19 mortality in Mexican patients with rheumatic and musculoskeletal diseases (RMDs) is unknown. Objectives: To describe characteristics of Mexican patients with RMDs and COVID-19, and to analyse factors associated with mortality. Methods: The Global Rheumatology Alliance COVID-19 (GRA) physician reported registry, is an international effort to collect information on COVID19 in adult patients with RMDs. GRA is an observational registry. The first patient from Mexico was registered on April 17, 2020. All Mexican patients registered in GRA until October 30, 2020 were included in this analysis. The association of mortality with demographic and clinical variables was estimated using logistic regression analysis. Results: A total of 323 patients were registered, with a median age of 52 (IQR 41-61) years old, 166 (51.4%) patients lived in Mexico City. The most frequent RMDs were rheumatoid arthritis, 149 (46.1%) and systemic lupus erythematosus, 24 (19.8%). Over a third of patients with RMDs and COVID-19 (119 (36.8%)) were hospitalized, and 43 (13.3%) died. Table 1 shows clinical and demographic characteristics. In the univariable analysis, the absence of comorbidities was a protective factor, OR 0.3 (95% CI 0.1-0.6). Factors associated with mortality at COVID-19 diagnosis were age over 65 years old, having type 2 diabetes, chronic renal insufficiency, treatment at COVID-19 diagnosis with corticosteroids or with CD20 inhibitors. In the multivariable adjusted analysis, these factors remained independently associated with mortality. No associations with other treatments or comorbidities at COVID-19 diagnosis were found. Conclusion: Mexican patients with RMDs and COVID-19 in the GRA physician reported registry had a mortality of 13.3%. Factors associated with mortality were those described in the general population, such as older age and being on corticosteroids and CD20 inhibitors treatment at COVID-19 diagnosis. References: [1]WHO. Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 . (accessed 26 January, 2021). [2]Zhou F, et al. Lancet 2020; 395 (10229):1054-62. Table 1. Clinical and demographic characteristics of patients with rheumatic diseases and COVID-19 in Mexico and mortality. Characteristics at COVID-19 diagnosis Total N=323 Death 43 (13.3) Survivors 280 (86.7) Univariable OR (95% CI) Multivariable OR (95% CI) Women, n(%) 268 (82.9) 33 (76.7) 235 (83.9) 0.6 (0.3-1.4) 0.5 (0.2-1.3) Age &gt;65 years old, n(%) 62 (19.2) 18 (41.9) 44 (15.7) 3.9 (1.9-7.7 ) 3.9 (1.9-8.3 ) RMDs* n(%) - Rheumatoid arthritis 149 (46.1) 23 (53.5) 126 (45.0) 1.6 (0.7-3.7) - Systemic Lupus Erythemathosus 64 (19.8) 10 (23.3) 54 (19.3) 1.6 (0.6-4.3) - Spondyloarthritis (axial and others) 33 (10.2) 2 (4.7) 31 (11.1) 0.1 (0.1-2.8) - Others 77 (23.8) 8 (18.6) 69 (24.6) 1 - Moderate/High disease activity 1 , n(%) 57 (18.6) 7 (17.9) 50 (18.7) 1.0 (0.4-2.5) - None comorbidities, n(%) 136 (42.1) 8 (18.6) 128 (45.7) 0.3 (0.1-0.6 ) - Hypertension*, n(%) 88 (27.2) 12 (27.9) 76 (27.1) 1.0 (0.5-2.1) - Type 2 Diabetes*, n(%) 49 (15.2) 13 (30.2) 36 (12.9) 2.9 (1.4-6.1 ) 2.4 (1.1-5.4 ) Obesity*, n(%) 21 (6.5) 3 (6.9) 18 (6.4) 1.1 (0.3-3.9) - Chronic obstructive pulmonary disease*, n(%) 15 (4.6) 1 (2.3) 14 (5.0) 0.5 (0.1-3.5) - Chronic renal insufficiency*, n(%) 17 (5.2) 6 (13.9) 11 (3.9) 3.9 (1.4-11.4 ) 3.4 (1.1-10.4 ) Cardiovascular diseases*, n(%) 14 (4.3) 2 (4.7) 12 (4.3) 1.1 (0.2-5.0) - Corticosteroids*, n(%) 171 (52.9) 30 (69.7) 141 (50.3) 2.3 (1.1-4.5 ) 3.0 (1.4-6.5 ) CsDMARD*, n(%) 247 (76.5) 33 (16.3) 214 (76.4) 1.0 (0.5- 2.2) - CD20 inhibitor*, n(%) 21 (6.5) 7 (16.3) 14 (5.0) 3.7 (1.4-9.9 ) 4.9 (1.7-14.5 ) *Overlapped, 1 307 patients. Disclosure of Interests: None declared